319 related articles for article (PubMed ID: 31734152)
1. Epoxyeicosatrienoic acid prevents maladaptive remodeling in pressure overload by targeting calcineurin/NFAT and Smad-7.
Li X; Chu G; Zhu F; Zheng Z; Wang X; Zhang G; Wang F
Exp Cell Res; 2020 Jan; 386(1):111716. PubMed ID: 31734152
[TBL] [Abstract][Full Text] [Related]
2. Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling pathway.
Ding W; Dong M; Deng J; Yan D; Liu Y; Xu T; Liu J
Am J Physiol Heart Circ Physiol; 2014 Sep; 307(5):H792-802. PubMed ID: 25015961
[TBL] [Abstract][Full Text] [Related]
3. Astragalus polysaccharide inhibits isoprenaline-induced cardiac hypertrophy via suppressing Ca²⁺-mediated calcineurin/NFATc3 and CaMKII signaling cascades.
Dai H; Jia G; Liu X; Liu Z; Wang H
Environ Toxicol Pharmacol; 2014 Jul; 38(1):263-71. PubMed ID: 24975447
[TBL] [Abstract][Full Text] [Related]
4. A gene therapeutic approach to inhibit calcium and integrin binding protein 1 ameliorates maladaptive remodelling in pressure overload.
Grund A; Szaroszyk M; Döppner JK; Malek Mohammadi M; Kattih B; Korf-Klingebiel M; Gigina A; Scherr M; Kensah G; Jara-Avaca M; Gruh I; Martin U; Wollert KC; Gohla A; Katus HA; Müller OJ; Bauersachs J; Heineke J
Cardiovasc Res; 2019 Jan; 115(1):71-82. PubMed ID: 29931050
[TBL] [Abstract][Full Text] [Related]
5. Carabin protects against cardiac hypertrophy by blocking calcineurin, Ras, and Ca2+/calmodulin-dependent protein kinase II signaling.
Bisserier M; Berthouze-Duquesnes M; Breckler M; Tortosa F; Fazal L; de Régibus A; Laurent AC; Varin A; Lucas A; Branchereau M; Marck P; Schickel JN; Deloménie C; Cazorla O; Soulas-Sprauel P; Crozatier B; Morel E; Heymes C; Lezoualc'h F
Circulation; 2015 Jan; 131(4):390-400; discussion 400. PubMed ID: 25369805
[TBL] [Abstract][Full Text] [Related]
6. Cardiomyocyte-specific expression of CYP2J2 prevents development of cardiac remodelling induced by angiotensin II.
He Z; Zhang X; Chen C; Wen Z; Hoopes SL; Zeldin DC; Wang DW
Cardiovasc Res; 2015 Mar; 105(3):304-17. PubMed ID: 25618409
[TBL] [Abstract][Full Text] [Related]
7. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
[TBL] [Abstract][Full Text] [Related]
8. CYP2J2/EET reduces vulnerability to atrial fibrillation in chronic pressure overload mice.
Li X; Zhu F; Meng W; Zhang F; Hong J; Zhang G; Wang F
J Cell Mol Med; 2020 Jan; 24(1):862-874. PubMed ID: 31749335
[TBL] [Abstract][Full Text] [Related]
9. Cisapride protects against cardiac hypertrophy via inhibiting the up-regulation of calcineurin and NFATc-3.
Zhou X; Zhang Q; Zhao T; Bai X; Yuan W; Wu Y; Liu D; Li S; Ju J; Chege Gitau S; Chu W; Xu C; Lu Y
Eur J Pharmacol; 2014 Jul; 735():202-10. PubMed ID: 24769415
[TBL] [Abstract][Full Text] [Related]
10. Mesenchymal Stem Cells and Cardiomyocytes Interplay to Prevent Myocardial Hypertrophy.
Cai B; Tan X; Zhang Y; Li X; Wang X; Zhu J; Wang Y; Yang F; Wang B; Liu Y; Xu C; Pan Z; Wang N; Yang B; Lu Y
Stem Cells Transl Med; 2015 Dec; 4(12):1425-35. PubMed ID: 26586774
[TBL] [Abstract][Full Text] [Related]
11. Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways.
Liu W; Deng J; Ding W; Wang G; Shen Y; Zheng J; Zhang X; Luo Y; Lv C; Wang Y; Chen L; Yan D; Boudreau RL; Song LS; Liu J
Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611128
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cardiac hypertrophy by aromadendrin through down-regulating NFAT and MAPKs pathways.
Cui S; Cui Y; Li Y; Zhang Y; Wang H; Qin W; Chen X; Ding S; Wu D; Guo H
Biochem Biophys Res Commun; 2018 Dec; 506(4):805-811. PubMed ID: 30389139
[TBL] [Abstract][Full Text] [Related]
13. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
Grebe C; Klingebiel TM; Grau SP; Toischer K; Didié M; Jacobshagen C; Dullin C; Hasenfuss G; Seidler T
Cardiovasc Res; 2011 Jun; 90(3):521-8. PubMed ID: 21273244
[TBL] [Abstract][Full Text] [Related]
14. Ginseng reverses established cardiomyocyte hypertrophy and postmyocardial infarction-induced hypertrophy and heart failure.
Moey M; Gan XT; Huang CX; Rajapurohitam V; Martínez-Abundis E; Lui EM; Karmazyn M
Circ Heart Fail; 2012 Jul; 5(4):504-14. PubMed ID: 22576957
[TBL] [Abstract][Full Text] [Related]
15. 6-Gingerol protects against cardiac remodeling by inhibiting the p38 mitogen-activated protein kinase pathway.
Ma SQ; Guo Z; Liu FY; Hasan SG; Yang D; Tang N; An P; Wang MY; Wu HM; Yang Z; Fan D; Tang QZ
Acta Pharmacol Sin; 2021 Oct; 42(10):1575-1586. PubMed ID: 33462378
[TBL] [Abstract][Full Text] [Related]
16. CYP2J2 and its metabolites (epoxyeicosatrienoic acids) attenuate cardiac hypertrophy by activating AMPKα2 and enhancing nuclear translocation of Akt1.
Wang B; Zeng H; Wen Z; Chen C; Wang DW
Aging Cell; 2016 Oct; 15(5):940-52. PubMed ID: 27416746
[TBL] [Abstract][Full Text] [Related]
17. Hsp90 Inhibitor Attenuates the Development of Pathophysiological Cardiac Fibrosis in Mouse Hypertrophy via Suppression of the Calcineurin-NFAT and c-Raf-Erk Pathways.
Marunouchi T; Nakashima M; Ebitani S; Umezu S; Karasawa K; Yano E; Tanonaka K
J Cardiovasc Pharmacol; 2021 Jun; 77(6):822-829. PubMed ID: 34016843
[TBL] [Abstract][Full Text] [Related]
18. Gallic Acid Suppresses Cardiac Hypertrophic Remodeling and Heart Failure.
Yan X; Zhang YL; Zhang L; Zou LX; Chen C; Liu Y; Xia YL; Li HH
Mol Nutr Food Res; 2019 Mar; 63(5):e1800807. PubMed ID: 30521107
[TBL] [Abstract][Full Text] [Related]
19. Betulinic Acid Protects DOX-Triggered Cardiomyocyte Hypertrophy Response through the GATA-4/Calcineurin/NFAT Pathway.
Yoon JJ; Son CO; Kim HY; Han BH; Lee YJ; Lee HS; Kang DG
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374365
[TBL] [Abstract][Full Text] [Related]
20. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation.
Donaldson C; Eder S; Baker C; Aronovitz MJ; Weiss AD; Hall-Porter M; Wang F; Ackerman A; Karas RH; Molkentin JD; Patten RD
Circ Res; 2009 Jan; 104(2):265-75, 11p following 275. PubMed ID: 19074476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
